Cardiovascular Health

New data show that pharmacist-led interventions in independent community pharmacies can move the needle on A1C, blood pressure, and stroke risk, even in rural and underserved settings.

Case reports show that alternative agents, including phenytoin, have been successful in resolving digoxin-induced arrhythmias.

Artificial intelligence is emerging as a vital tool for pharmacists in cardiovascular care—supporting clinical decisions, patient education, and adherence while maintaining guideline alignment.

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, breaks down the key distinctions between obstructive and nonobstructive hypertrophic cardiomyopathy (oHCM) and explains how cardiac myosin inhibitors target the underlying disease mechanism.

New American College of Cardiology/American Heart Association dyslipidemia guidelines reset LDL goals, add PREVENT risk scoring, and expand Lp(a)/apoB testing for earlier, tougher prevention.

Explore how pharmacists elevate electrophysiology care and get a preview of ACC 2026 trials on AF, HFpEF, pulmonary embolism, and hypertension.

Despite persistent gaps in cardiovascular risk management, pharmacists are proving essential in improving LDL control, guiding statin use, and supporting evidence-based care across clinical settings.

An Intermountain Health study finds atrial fibrillation present in 25% of patients with peripheral arterial disease, with major cardiovascular events occurring in 46% within 3 years.

Pharmacists have become central to titration, access, patient education, and logistics as GLP-1 use grows and cardiometabolic management evolves.

Experts discuss guideline adoption, therapeutic advances, and team-based care.

Laxmi Mehta, MD, explains how pharmacists can counsel patients on inherited lipid risk factors like lipoprotein(a) and why combining pharmacologic therapy with lifestyle modification is essential for reducing cardiovascular risk.

Experts discuss practice expansion, guideline updates, and team-based care.

Allison Burnett, PharmD, joins The Tell-Tale Heart to break down the first-ever ACC/AHA acute pulmonary embolism guidelines.

Lomitapide demonstrated substantial LDL cholesterol reductions in a pivotal trial.

Sheryl L. Chow, PharmD, outlines the pharmacist's evolving role in cardiovascular prevention, heart failure management, and medication adherence during American Heart Month and beyond.

Explore PREVENT Risk Equations reshaping hypertension care, HFpEF therapy, and CKD-related hyperkalemia.

Awareness of the nonlinear response helps ensure patients are treated with the least intensive regimen that achieves meaningful control while minimizing harm and improving long-term therapeutic success.

Laxmi Mehta, MD, discusses widespread patient unawareness of nonstatin cholesterol therapies, common statin misconceptions, and the critical role pharmacists play in bridging the lipid treatment knowledge gap.

The guideline establishes a novel clinical classification framework and recommends direct oral anticoagulants over vitamin K antagonists for eligible patients.

Experts Craig Beavers and Kristen Campbell discuss what pharmacists should know heading into ACC 26.

Sarah Nelson, PharmD, highlights how pharmacists are uniquely positioned to prevent heart disease by identifying cardiovascular risk early, improving medication adherence, and addressing lifestyle and social factors.

Craig Beavers, PharmD, explores new phase 3 evidence on factor XIa inhibitors for secondary stroke prevention, highlighting OCEANIC-STROKE results, safety, and patient selection.

Joseph Saseen, PharmD, explains how population health strategies and team-based care create new opportunities for pharmacists to identify lipid treatment gaps and lead evidence-based ASCVD prevention.

Universal aspirin at the first prenatal visit lowers severe preeclampsia rates in high-risk pregnancies, delaying onset without raising hemorrhage or placental abruption risk.

Joseph Saseen, PharmD, highlights how pharmacists can close treatment gaps in dyslipidemia by initiating appropriate statin intensity early, using combination therapy when needed, and proactively assessing adherence.